223 related articles for article (PubMed ID: 23357084)
1. Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol.
de Bartolomeis A; Marmo F; Buonaguro EF; Rossi R; Tomasetti C; Iasevoli F
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1516-29. PubMed ID: 23357084
[TBL] [Abstract][Full Text] [Related]
2. Switching antipsychotics: Imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-naïve vs. antipsychotic-exposed rats.
de Bartolomeis A; Marmo F; Buonaguro EF; Latte G; Tomasetti C; Iasevoli F
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Oct; 70():24-38. PubMed ID: 27177972
[TBL] [Abstract][Full Text] [Related]
3. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
[TBL] [Abstract][Full Text] [Related]
4. Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: insights for psychosis treatment.
de Bartolomeis A; Iasevoli F; Marmo F; Buonaguro EF; Eramo A; Rossi R; Avvisati L; Latte G; Tomasetti C
Eur Neuropsychopharmacol; 2015 Apr; 25(4):566-82. PubMed ID: 25649681
[TBL] [Abstract][Full Text] [Related]
5. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
6. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality.
Möller HJ
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1101-11. PubMed ID: 14642970
[TBL] [Abstract][Full Text] [Related]
7. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
[TBL] [Abstract][Full Text] [Related]
8. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
[TBL] [Abstract][Full Text] [Related]
9. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action.
Hertel P
Synapse; 2006 Dec; 60(7):543-52. PubMed ID: 16952163
[TBL] [Abstract][Full Text] [Related]
10. Amisulpride: a review of its use in the management of schizophrenia.
Curran MP; Perry CM
Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
[TBL] [Abstract][Full Text] [Related]
11. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat.
Cudennec A; Fage D; Bénavidès J; Scatton B
Brain Res; 1997 Sep; 768(1-2):257-65. PubMed ID: 9369323
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
13. Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions.
Iasevoli F; Fiore G; Cicale M; Muscettola G; de Bartolomeis A
Psychiatry Res; 2010 May; 177(1-2):255-60. PubMed ID: 20304506
[TBL] [Abstract][Full Text] [Related]
14. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
15. The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes.
Tomasetti C; Dell'Aversano C; Iasevoli F; Marmo F; de Bartolomeis A
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):184-97. PubMed ID: 21055435
[TBL] [Abstract][Full Text] [Related]
16. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study.
Meisenzahl EM; Schmitt G; Gründer G; Dresel S; Frodl T; la Fougère C; Scheuerecker J; Schwarz M; Boerner R; Stauss J; Hahn K; Möller HJ
Pharmacopsychiatry; 2008 Sep; 41(5):169-75. PubMed ID: 18763218
[TBL] [Abstract][Full Text] [Related]
17. Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia.
Buonaguro EF; Tomasetti C; Chiodini P; Marmo F; Latte G; Rossi R; Avvisati L; Iasevoli F; de Bartolomeis A
J Psychopharmacol; 2017 Apr; 31(4):406-417. PubMed ID: 27443599
[TBL] [Abstract][Full Text] [Related]
18. Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons.
Di Giovanni G; Di Mascio M; Di Matteo V; Esposito E
J Pharmacol Exp Ther; 1998 Oct; 287(1):51-7. PubMed ID: 9765321
[TBL] [Abstract][Full Text] [Related]
19. Is amisulpride an 'atypical' atypical antipsychotic agent?
Lecrubier Y
Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
[TBL] [Abstract][Full Text] [Related]
20. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.
Kiss B; Laszlovszky I; Horváth A; Némethy Z; Schmidt E; Bugovics G; Fazekas K; Gyertyán I; Agai-Csongor E; Domány G; Szombathelyi Z
Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):515-28. PubMed ID: 18551280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
